Cogent Biosciences, Inc. (COGT)

Cogent Biosciences has experienced positive clinical trial results and regulatory milestones, including positive topline results from the Phase 3 PEAK trial and APEX trial, NDA submission for bezuclastinib, and initiation of the PEAK NDA under the FDA's RTOR and BTD programs, contributing to a substantial increase in the stock price. The company completed public offerings of common stock and convertible senior notes, generating net proceeds of approximately $546.8 million, and reported a net loss of $102.5 million for the fourth quarter of 2025. There was a major insider sale on January 22, 2026, but institutional investors have significantly increased their stakes.

Cogent Biosciences is a clinical-stage biotechnology company without established demand seasonality for its products and services. Demand for its therapies is primarily driven by disease prevalence, diagnosis rates, and market penetration following regulatory approvals and commercialization efforts.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, particularly in oncology and hematology. Their lead product candidate is bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor targeting the KIT D816V mutation in Systemic Mastocytosis (SM) and other mutations in KIT exon 17 in advanced gastrointestinal stromal tumors (GIST). The company also has a pipeline of other targeted therapies in various stages of development, including CGT4859, CGT4255, CGT6297, CGT1145, and a pan-KRAS inhibitor.

Cogent Biosciences' corporate headquarters are located in Waltham, Massachusetts, and they also maintain operations in Boulder, Colorado. These locations support the company's corporate, clinical, and research functions for its precision oncology and hematology programs.

Cogent Biosciences' brand reputation has been largely positive due to successful clinical trial results, regulatory achievements for bezuclastinib, and positive analyst sentiment. The company's strong cash position, expected to fund operations into 2028, also contributes to a positive outlook, despite ongoing net losses typical of a clinical-stage biotech.

Cogent Biosciences has significant institutional ownership, with 273 institutional owners and shareholders holding approximately 92.60% of the company. Insiders own about 7.40%. Major institutional owners include Fmr Llc, BlackRock, Inc., Vanguard Group Inc, Deerfield Management Company, L.p., Fairmount Funds Management LLC, Rtw Investments, Lp, Kynam Capital Management, LP, TCG Crossover Management, LLC, State Street Corp, and Janus Henderson Group Plc. Fairmount Funds Management LLC is also the largest individual shareholder.